Literature DB >> 31651223

Major challenges in accurate mutation detection of multifocal lung adenocarcinoma by next-generation sequencing.

Tian Qiu1, Weihua Li1, Fanshuang Zhang1, Bingning Wang1, Jianming Ying1.   

Abstract

Background: Many patients with advanced non-small cell lung cancer manifested with metastasis, and molecular heterogeneity may exhibit between primary and metastatic tumors. We sought to investigate the clinical detection strategy of primary and metastatic tumors in Chinese patients with NSCLC.
Methods: Here, 77 paired tumors of Chinese patients with lung adenocarcinoma were analyzed, and 1836 mutation in hotspot regions of 22 genes were identified by next-generation sequencing. The expression of ALK in these paired tumors was also detected by immunohistochemistry.
Results: The results showed that the concordance rate in multiple pulmonary nodules, primary-LN metastasis pairs and primary-distant metastasis pairs was 67.7%, 94.1% and 86.7%, respectively. In multiple pulmonary nodules, the concordance rate was 100% when the pathologic diagnosis was intrapulmonary metastasis, whereas the concordance rate was 23.1% when the pathologic diagnosis was multiple primary tumors. TP53 and CTNNB1 mutations were detected as the recurrent alterations in LN metastasis. Moreover, the concordance of ALK status was observed in these pairs.Conclusions: Our data suggested that hotspot mutations and ALK status in the primary-metastasis pairs had a high concordance in lung adenocarcinoma. Clinical detection of one lesion may be enough to identify the key alterations except that patients are diagnosed with multiple primary tumors or have disease progression after benefiting from target therapy.

Entities:  

Keywords:  Lung adenocarcinoma; immunohistochemistry; mutation; next-generation sequencing; tumor heterogeneity

Year:  2019        PMID: 31651223      PMCID: PMC7012153          DOI: 10.1080/15384047.2019.1674070

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  31 in total

1.  KRAS mutation status in primary nonsmall cell lung cancer and matched metastases.

Authors:  Alexis B Cortot; Antoine Italiano; Fanny Burel-Vandenbos; Ghyslaine Martel-Planche; Pierre Hainaut
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

2.  Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases--an analysis by comparative genomic hybridization.

Authors:  Jeng-Kai Jiang; Yann-Jang Chen; Chi-Hung Lin; I-Ting Yu; Jen-Kou Lin
Journal:  Genes Chromosomes Cancer       Date:  2005-05       Impact factor: 5.006

3.  Intranodal palisaded myofibroblastoma: another mesenchymal neoplasm with CTNNB1 (β-catenin gene) mutations: clinicopathologic, immunohistochemical, and molecular genetic study of 18 cases.

Authors:  William B Laskin; Jerzy P Lasota; John F Fetsch; Anna Felisiak-Golabek; Zeng-Feng Wang; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2015-02       Impact factor: 6.394

4.  Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline.

Authors:  Natasha B Leighl; Natasha Rekhtman; William A Biermann; James Huang; Mari Mino-Kenudson; Suresh S Ramalingam; Howard West; Sara Whitlock; Mark R Somerfield
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

5.  Genetic analysis of colon tumors induced by a dietary carcinogen PhIP in CYP1A humanized mice: Identification of mutation of β-catenin/Ctnnb1 as the driver gene for the carcinogenesis.

Authors:  Hong Wang; Hong Zhou; Anna Liu; Xiangyi Guo; Chung S Yang
Journal:  Mol Carcinog       Date:  2014-08-17       Impact factor: 4.784

Review 6.  The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.

Authors:  Samuel J Klempner; Sai-Hong Ignatius Ou; Daniel B Costa; Paul A VanderLaan; Eric M Sanford; Alexa Schrock; Laurie Gay; Siraj M Ali; Vincent A Miller
Journal:  Clin Lung Cancer       Date:  2015-03-26       Impact factor: 4.785

Review 7.  Contribution of p53 to metastasis.

Authors:  Emily Powell; David Piwnica-Worms; Helen Piwnica-Worms
Journal:  Cancer Discov       Date:  2014-03-21       Impact factor: 39.397

8.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

Review 9.  TP53 mutations in nonsmall cell lung cancer.

Authors:  Akira Mogi; Hiroyuki Kuwano
Journal:  J Biomed Biotechnol       Date:  2011-01-18

Review 10.  Mechanisms of resistance to EGFR tyrosine kinase inhibitors.

Authors:  Lihua Huang; Liwu Fu
Journal:  Acta Pharm Sin B       Date:  2015-07-26       Impact factor: 11.413

View more
  2 in total

1.  Differential Diagnostic Value of Histology in MPLC and IPM: A Systematic Review and Meta-Analysis.

Authors:  Sen Tian; Fuqi Li; Jin Pu; Yi Zheng; Hui Shi; Yuchao Dong; Ruohua Chen; Chong Bai
Journal:  Front Oncol       Date:  2022-04-29       Impact factor: 5.738

2.  Establishment of Criteria for Molecular Differential Diagnosis of MPLC and IPM.

Authors:  Xiaohui Wang; Yuan Gong; Jianfei Yao; Yan Chen; Yuemin Li; Zhen Zeng; Yinying Lu; Lele Song
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.